Kurmann, Thomas http://orcid.org/0000-0002-9320-1623
Yu, Siqing
Márquez-Neila, Pablo
Ebneter, Andreas
Zinkernagel, Martin
Munk, Marion R.
Wolf, Sebastian http://orcid.org/0000-0002-7467-7028
Sznitman, Raphael
Funding for this research was provided by:
Innosuisse Grant # 6362.1 PFLS-LS
Article History
Received: 18 February 2019
Accepted: 29 August 2019
First Online: 19 September 2019
Competing Interests
: R.S. has received speaker fees from Bayer AG and is a shareholder of RetinAI Medical AG. M.R.M is a consultant for Zeiss, Bayer, Novartis and Lumithera. M.Z. is a consultant for Heidelberg, Bayer and Novartis. A.E. reports other from Allerga, other from Bayer, other from Novartis and other from Plexxikon Inc. S.W. reports other from Bayer AG, other from Allergan, other from Novartis Pharma, other from Heidelberg Engineering, other from Zeiss, other from Chengdu Kanghong, other from Roche, outside the submitted work. The authors have no other competing interests to disclose.